VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
Portfolio Pulse from
Vertex Pharmaceuticals' shares fell after announcing phase II study results for its non-opioid pain drug, suzetrigine, which showed similar pain reduction to a placebo in treating lumbosacral radiculopathy.
December 20, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vertex Pharmaceuticals' shares declined following the release of phase II study results for suzetrigine, a non-opioid pain drug, which showed no significant difference in pain reduction compared to a placebo.
The phase II study results for suzetrigine, a key drug in Vertex's pipeline, showed it was no more effective than a placebo, leading to a negative market reaction and a drop in VRTX shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100